Cytosorbents (CTSO) Depreciation & Amortization (CF) (2010 - 2026)

Cytosorbents (CTSO) has reported Depreciation & Amortization (CF) for 17 consecutive years, with -$351000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) rose 13.12% year-over-year to -$351000.0; the trailing twelve-month figure through Jun 2026 stood at -$618000.0 (down 133.65% YoY), and the FY2025 full-year result was $1.2 million, down 7.57% from the prior year.
• Depreciation & Amortization (CF) fell to -$351000.0 in Q2 2026 per CTSO's latest filing, from $97000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $407208.0 in Q3 2023 and bottomed at -$404000.0 in Q2 2025.
• Historically, Depreciation & Amortization (CF) has averaged $85616.2 across 5 years, with a median of $217565.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) soared 91.11% in 2023, then plunged 199.76% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $223214.0 in 2022, then jumped by 75.29% to $391269.0 in 2023, then slumped by 60.64% to $154000.0 in 2024, then slumped by 37.01% to $97000.0 in 2025, then slumped by 461.86% to -$351000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered -$351000.0, $97000.0, and -$364000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.